<DOC>
	<DOCNO>NCT00381264</DOCNO>
	<brief_summary>This study design evaluate safety efficacy Cesamet™ control pain subject experience pain due Multiple Sclerosis .</brief_summary>
	<brief_title>Evaluation Efficacy Cesamet™ Treatment Pain Patients With Multiple Sclerosis</brief_title>
	<detailed_description>The purpose study determine safety efficacy Cesamet™ symptomatic treatment pain due Multiple Sclerosis . This phase IV , multi-center , open label outpatient clinical trial evaluate Cesamet™ treatment control pain due MS . The study two phase : Pretreatment Phase Treatment Phase .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Nabilone</mesh_term>
	<criteria>Patients diagnose MS Chronic daily pain present least 2 month . On stable analgesic regimen one month Baseline pain score great 40mm visual analog scale . Hypersensitivity compound study drug similar drug Pregnant lactate female Drug alcohol abuse Unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>